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The principles and practice of stereotac-
tic body radiotherapy (SBRT) were trans-
ferred from cranial stereotactic radiother-
apy/radiosurgery in the mid-1990s by pi-
oneering work at the Karolinska Hospi-
tal in Sweden [1]. This concept was quick-
ly adopted and further developed in Ja-
pan [2] and Germany [3, 4]. At the begin-
ning, SBRT was predominantly defined by 
frame-based stereotactic patient setup for 
accurate delivery of conformal dose dis-
tributions to extracranial targets in hypo-
fractionated irradiation schemes. Nowa-
days however, a commonly accepted def-
inition of SBRT does not exist. This is be-
cause frame-based stereotactic patient set-
up has been replaced by image guidance, 
which renders the term stereotactic mis-
leading.
The Stereotactic Radiotherapy Work-
ing Group was asked by the German So-
ciety of Radiation Oncology (Deutschen 
Gesellschaft für Radioonkologie, DE-
GRO) to provide a definition of SBRT and 
to give an evidence-based review of cur-
rent SBRT practice. This article will focus 
on the definition of SBRT, as well as the in-
dications for and practice and outcome of 
SBRT for early stage non-small cell lung 
cancer (NSCLC).
Definition of SBRT
National working groups in several dif-
ferent countries have reported their def-
initions of SBRT. The definitions of 
SBRT provided by the American Asso-
ciation of Physics in Medicine (AAPM) 
Task Group 101; the American Society 
for Therapeutic Radiology and Oncolo-
gy and the American College of Radiolo-
gy  (ASTRO and ACR); the Canadian As-
sociation of Radiation Oncology—Stereo-
tactic Body Radiotherapy (CARO-SBRT) 
and the National Radiotherapy Imple-
mentation Group of the UK [5, 6, 7, 8] all 
agree on the following items: SBRT is (1) 
a method of external beam radiotherapy 
(EBRT) that (2) accurately delivers a (3) 
high dose of irradiation in (4) one or few 
treatment fractions to an (5) extracrani-
al target.
These essential components of the 
SBRT definition are specified in more de-
tail below:
1.  SBRT can be adequately performed 
with either traditional linear accel-
erators equipped with suitable im-
age-guidance technology, accelerators 
specifically adapted for SBRT or ded-
icated delivery systems. Additionally, 
the principles of SBRT apply for both 
photon and particle therapy.
2.  It is of fundamental importance that 
the entire SBRT workflow be system-
atically optimized and that appro-
priate quality assurance (QA) mea-
sures are implemented. From a clin-
ical perspective, the term “accurate” 
covers disease staging; multidisci-
plinary discussion of the indications 
for SBRT; tumor site adjusted imaging 
with appropriate spatial and tempo-
ral resolution for target and organ at 
risk (OAR) definition; highly confor-
mal treatment; image-guided patient 
setup; active or passive intrafraction 
motion management and follow-up 
(preferably at the treating institution). 
From a physics perspective, SBRT re-
quires additional and more sophis-
ticated QA procedures compared to 
conventional radiotherapy. These in-
clude system-specific end-to-end tests 
for both static and moving targets, as 
well as verification of the alignment 
of imaging and treatment isocenters 
prior to SBRT on a daily basis.
3.  Radiation doses are at least equivalent 
to radical doses in conventional frac-
tionation.
4.  Radiation doses are delivered in few 
fractions (usually but not necessari-
ly in a maximum of 10 fractions). Ad-
justment of single-fraction dose and 
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total dose to volume and location of 
the target is essential.
5.  The target is accurately localized us-
ing tumor site specific imaging mo-
dalities. Simultaneously, the target 
needs to be spatially separated from 
critical OARs, without diffuse infiltra-
tion into these. Only the macroscop-
ic target and small, immediately adja-
cent volumes of potential microscopic 
spread are treated in SBRT.
 
The term “stereotactic” is still considered 
appropriate for SBRT, even if no frame-
based patient setup using external stereo-
tactic coordinates is performed; the ex-
ternal coordinates are replaced by the in-
ternal coordinates of the image guidance 
procedure. These images must either visu-
alize and locate the target itself or surro-
gate anatomical structures/fiducial mark-
ers that are closely correlated to the target.
Stereotactic ablative radiotherapy 
 (SABR) has been proposed by an inter-
national group of authors as an alterna-
tive to SBRT [9]. However, our opinion 
on the appropriateness of “ablative” dif-
fers because it does not accurately de-
scribe the radiobiology and clinical out-
come of SBRT in all its variations. Tech-
niques like radiofrequency ablation (RFA) 
are ablative irrespective of the normal or 
neoplastic nature of the tissue in the treat-
ed volume, which makes treatment of tu-
mors abutting critical serial OARs impos-
sible. In contrast, SBRT allows tumoricid-
al treatment of such targets while sparing 
the OARs through the differences in ra-
diosensitivity of normal and cancerous 
tissue, as well as through fractionation ef-
fects.
SBRT for early stage NSCLC
Rationale for SBRT
After detection of NSCLC at an early 
stage (as is the case in 20–30% of all pa-
tients), the best overall survival (OS) with 
cure rate in the majority of the patients is 
achieved by surgical lobectomy and sys-
tematic mediastinal lymph node dissec-
tion. However, surgical resection is not 
possible in a substantial proportion of 
patients—about 20% of all patients with 
stage I NSCLC [10]—because of comor-
bidities or insufficient pulmonary func-
tion resulting from tobacco abuse and 
consequent chronic obstructive pulmo-
nary disease (COPD). This fraction of in-
operable patients is expected to further in-
crease due to aging western populations: 
only 40% of patients aged 75 years or old-
er are treated surgically for stage I NSCLC 
in the Netherlands [11]. If no treatment is 
offered to these patients, cancer leads to 
death within few years despite its early 
stage [10].
In cases of contraindication for radi-
cal lobectomy, the standard treatment op-
tions are best supportive care (BSC), con-
ventionally fractionated radiotherapy and 
sublobar resection. The therapy of choice 
depends on the patient’s performance sta-
tus, age and comorbidities.
Based on the California Cancer Cen-
ter registry, 7% of all patients with stage I 
NSCLC are treated with BSC alone be-
cause their life expectancy is considered 
too short for curative treatment [10]. 
Among the elderly population, this pro-
portion of untreated patients increases to 
30% [11, 12]. However, 5-year lung cancer 
specific survival rates are less than 20% in 
untreated patients, indicating the need for 
a curative treatment option that is effec-
tive and simultaneously safe for this pa-
tient population.
Conventionally fractionated radiother-
apy is an established curative treatment 
option for stage I NSCLC, with 3-year OS 
rates of about 30% [13]. However, local 
tumor relapse is the most frequent cause 
of treatment failure after irradiation with 
conventionally fractionated doses of 60–
66 Gy [13, 14]. Retrospective studies have 
demonstrated a dose–response relation-
ship for local tumor control and disease 
specific survival in NSCLC [15, 16, 17], 
which clearly indicates the need for a ra-
diotherapy methodology that enables a 
safe intensification of treatment.
Sublobar resection is practiced in bor-
derline operable patients as an alternative 
to lobectomy. This technique spares lung 
tissue and preserves pulmonary function 
compared to lobectomy. However, the re-
sults of a randomized controlled trial [18] 
indicate that this is associated with inferi-
or oncological outcome.
Clinical outcome after SBRT 
for early stage NSCLC and 




Two recent population-based analyses 
from the Netherlands [11, 12] and one 
from the US [19] demonstrated an im-
provement in OS for stage I NSCLC by 
the introduction of SBRT into the elderly 
patient population. OS was improved by 
shifting patients from BSC or convention-
ally fractionated radiotherapy to SBRT, 
treatment options which are both inferi-
or to SBRT. Further studies showed that 
SBRT is safely practiced in patients with 
severe pulmonary comorbidities and very 
poor pretreatment pulmonary function 
and toxicity was not increased in these 
high-risk patient populations [20, 21]. 
Consequently, SBRT should be offered 
to all patients—irrespective of advanced 
age or pre-existing pulmonary comorbid-
ities—unless their survival expectancy is 
very short. The SBRT characteristics of a 
noninvasive treatment delivered in a few 
fractions on an outpatient basis are ex-





Several prospective phase II trials of SBRT 
in medically inoperable stage I NSCLC 
patients have reported local tumor con-
trol rates of 84–98% [22, 23, 24, 25, 26, 27], 
demonstrating consistent results despite 
differences in SBRT methodology. This 
improved local tumor control compared 
to conventional radiotherapy [13] trans-
fers into improved OS, as demonstrated in 
meta- [28] and population-based analy ses 
[19]: 3-year OS is approximately 50% af-
ter SBRT, with pretreatment comorbidi-
ties being a strong predictor for OS [29]. 
Based on these findings and the 1.2013 
version of the National Comprehensive 
Cancer Network (NCCN) Guidelines for 
NSCLC [30], SBRT is today considered 
superior to conventionally fractionated 
radiotherapy and is the standard of care 
for medically inoperable patients.
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SBRT vs. RFA
RFA has been introduced as a minimal-
ly invasive treatment option for stage I 
NSCLC. No study has performed a di-
rect comparison between SBRT and RFA, 
but a recent literature review reported im-
proved local tumor control, cancer specif-
ic survival and OS after SBRT compared 
to RFA [31]. Additionally, toxicity and 30-
day mortality [32] were lower after SBRT, 
resulting in the conclusion that SBRT 
should be proposed as the initial nonsur-
gical treatment in high-risk patients.
SBRT vs. sublobar resection in 
high surgical risk patients
There are few studies directly compar-
ing SBRT and sublobar resection for early 
stage NSCLC. Grills et al. [33] performed 
a single-institution comparison between 
SBRT and wedge resection. These authors 
reported improved local tumor control af-
ter SBRT, while no differences in regional 
control and cancer specific survival were 
observed. The previously cited US pop-
ulation-based analysis showed identi-
cal OS and cancer specific survival rates 
for SBRT and sublobar resection [19]: 30-
day mortality rates were 0 and 1.2% af-
ter SBRT and sublobar resection, respec-
tively. Consequently, current data support 
both SBRT and sublobar resection as via-
ble treatment alternatives for high surgi-
cal risk patients. The results of a current-
ly recruiting American College of Sur-
geons Oncology Group randomized trial 





The criteria for being fit enough to un-
dergo lobectomy are described in nation-
al and international guidelines. Lobecto-
my is considered to be the treatment of 
choice for stage I NSCLC if these criteria 
are met. Few studies have reported out-
come after SBRT where surgical resection 
was refused by the patients. Two Japanese 
and Dutch studies described excellent OS 
rates of 70% after 5 years [34] and 85% 
at 3 years [35], respectively. Two recent 
matched-pair analyses reported equiva-
lent OS [36] and equivalent disease-free 
survival rates [37] after SBRT and lobecto-
my. Consequently, SBRT is a viable treat-
ment option in the situation of surgical 
treatment being refused by the patient.
Recommendations for 
clinical practice of SBRT 
in early stage NSCLC
Clinical evaluation
Careful assessment of performance status 
is important to enable a sensible therapy 
concept. Perioperative morbidity is asso-
ciated with older age (>70 years) and the 
presence of comorbidities [38, 39]. There-
fore, pulmonary function tests, as well as 
cardiac and performance status assess-
ment are recommended before estimat-
ing the operative risk. As a corollary of 
this, the indication for SBRT should be 




Histopathological confirmation of disease 
is recommended. Transbronchial biopsy 
or transthoracic needle aspiration are pri-
mary methods. Nevertheless, demonstra-
tion of malignancy is sometimes impos-
sible or associated with an unacceptably 
high risk because of the medical and/or 
pulmonary comorbidities of the patient. 
In this case, radiological criteria of malig-
nancy should be consulted.
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Definition of stereotactic body radiotherapy. Principles and 
practice for the treatment of stage I non-small cell lung cancer
Abstract
This report from the Stereotactic Radiother-
apy Working Group of the German Society 
of Radiation Oncology (Deutschen Gesell-
schaft für Radioonkologie, DEGRO) provides 
a definition of stereotactic body radiothera-
py (SBRT) that agrees with that of other inter-
national societies. SBRT is defined as a meth-
od of external beam radiotherapy (EBRT) that 
accurately delivers a high irradiation dose 
to an extracranial target in one or few treat-
ment fractions. Detailed recommendations 
concerning the principles and practice of 
SBRT for early stage non-small cell lung can-
cer (NSCLC) are given. These cover the en-
tire treatment process; from patient selection, 
staging, treatment planning and delivery to 
follow-up. SBRT was identified as the method 
of choice when compared to best supportive 
care (BSC), conventionally fractionated radio-
therapy and radiofrequency ablation. Based 
on current evidence, SBRT appears to be on 
a par with sublobar resection and is an effec-
tive treatment option in operable patients 
who refuse lobectomy.
Keywords
Organs at risk · Survival · Toxicity · Patient 
positioning · Quality assurance
Definition der stereotaktischen Strahlentherapie. Behandlung 
des nichtkleinzelligen Bronchialkarzinoms (NSCLC) Grad I
Zusammenfassung
Die Arbeitsgruppe „Stereotaktische Radio-
therapie“ der Deutschen Gesellschaft für Ra-
dioonkologie (DEGRO) erarbeitete eine Defi-
nition der Körperstereotaxie (SBRT), die sich 
an vorhandene internationale Definitionen 
anlehnt: Die SBRT ist eine Form der perku-
tanen Strahlentherapie, die mit hoher Präzi-
sion eine hohe Bestrahlungsdosis in einer 
oder wenigen Bestrahlungsfraktionen in ei-
nem extrakraniellen Zielvolumen appliziert. 
Zur Praxis der SBRT beim nichtkleinzelligen 
Bronchialkarzinom (NSCLC) im frühen Stadi-
um werden detaillierte Empfehlungen gege-
ben, die den gesamten Ablauf der Behand-
lung von der Indikationsstellung, Staging, Be-
handlungsplanung und Applikation  sowie 
Nachsorge umfassen. Die  Körperstereotaxie 
wurde als Methode der Wahl im Vergleich zu 
Best Supportive Care, zur konventionell frak-
tionierten Strahlentherapie sowie zur Ra-
diofrequenzablation identifiziert. Die Ergeb-
nisse nach SBRT und sublobärer Resektion er-
scheinen auf aktueller Datenbasis ebenbür-
tig. Die SBRT ist die Methode der Wahl, wenn 
Patienten einen operativen Eingriff in Form 
der Lappenresektion ablehnen.
Schlüsselwörter




Swensen et al. [40] described a predic-
tion model to estimate the probability of 
malignancy in solitary pulmonary nod-
ules (SPN) based on clinical and radio-
graphic characteristics. This model was 
validated by Herder et al. [41]. Inclusion 
of fluorodeoxyglucose positron-emission 
tomography (FDG-PET) imaging might 
further improve the accuracy of the pre-
diction model [42, 43]. If malignancy is 
highly likely based on the described crite-
ria, immediate SBRT without histopath-
ological confirmation is justified [44], as 
is also standard practice in thoracic sur-
gery [45]. Repeated imaging to evaluate 
the growth pattern is an option in patients 
with a borderline risk of malignancy, but 
this might put the patient at risk of dis-
ease progression in the time interval [46].
Staging of disease
In accordance with other groups [47], 
the DEGRO working group recommends 
the following staging procedures prior to 
SBRT: a CT scan of the chest including the 
upper abdomen using intravenous con-
trast is mandatory. A whole body FDG-
PET/CT scan should be performed in all 
cases. The added value of FDG-PET lies in 
the higher diagnostic accuracy for the de-
tection of nodal metastases (negative pre-
dictive value: 90%) [48, 49]; furthermore, 
distant metastases and clinically relevant 
second malignancies can be excluded. The 
PET/CT scan should not be older than 
6 weeks. In case of pathological FDG up-
take in mediastinal lymph nodes, further 
histopathological evaluation, e.g. by endo-
scopic ultrasound (EUS)- or endobron-
chial ultrasound (EBUS)-guided biopsy is 
mandatory. If the situation is still unclear, 
a mediastinoscopy may be necessary.
After exclusion of nodal metastases, 
SBRT is recommended for early stage 
NSCLC with a maximum tumor diame-
ter ≤5 cm. Only limited data are available 
about the safety and efficacy of SBRT for 
lesions larger than 5 cm, where the risk of 




Obviously, all images must be acquired 
in the treatment position. The planning 
CT scan should include the entire lung 
volume. Acquiring CT scans with a slice 
thickness of 2–3 mm is recommended. 
Use of intravenous contrast for CT scan-
ning improves delineation of centrally lo-
cated primary tumors. However, the use 
of synchronous intravenous contrast with 
four-dimensional CT (4D-CT) scans of 
the thorax is not established.
Due to the risk of artifacts and system-
atic errors introduced by the nonrepresen-
tative nature of the captured breathing po-
sition, the use of a 4D-CT (also known as 
respiration-correlated CT) scan is strong-
ly recommended for treatment planning 




A gross tumor volume (GTV) should be 
defined based on CT findings in lung and 
soft tissue windows including all small 
spiculae. Most centers do not use clinical 
target volume (CTV) margins to account 
for microscopic tumor extensions. How-
ever, practices pertaining to CTV defi-
nition are inconsistent. Caution is there-
fore advised when applying this concept 
to SBRT target volume definition, as the 
applied safety margins may unnecessari-
ly increase target volumes.
Integration of breathing-induced tar-
get motion into the target volume con-
cept is a prerequisite for ensuring prop-
er tumor targeting in individual patients. 
Clinical implementation depends on the 
respective motion management strategy, 
which in turn is required for SBRT.
Several different approaches can be ap-
plied and have already been implement-
ed into routine practice: continuous ir-
radiation during free breathing using (a) 
the internal target volume concept (ITV; 
most commonly practiced), (b) the mean 
target position concept [50] or (c) real-
time tumor tracking. Irradiation in spe-
cific breathing phases is performed us-
ing (a) gated beam delivery, (b) voluntary 
breath holding or (c) breath holding using 
the Active Breathing Coordinator (Elekra, 
Stockholm, Sweden). Multiple planning 
studies reported reduced safety margins 
by the use of individually tailored patient 
motion compensation strategies com-
pared to population-based margins.
Although patient-specific motion 
management is strongly recommended, 
it is important to note that no prospec-
tive trials have used advanced motion 
management strategies. Furthermore, no 
benefit of advanced motion management 
strategies like gating or tracking has been 




Wherever possible, dose prescription and 
reporting should comply with the Inter-
national Commission on Radiation Units 
(ICRU) Report 83. ICRU recommends 
prescribing to the median (D50), or alter-
natively, to the mean (Dmean) dose. Based 
on experiences with cranial stereotactic 
radiotherapy, SBRT is practiced using in-
homogeneous dose distributions within 
the planning target volume (PTV); max-
imum PTV doses range between 105 and 
150% of the prescribed PTV-encompass-
ing dose. Effective doses to the GTV fur-
ther vary according to the applied GTV-
to-PTV safety margins and the size of the 
macroscopic tumor. We therefore recom-
mend reporting minimum (D95 or D98) 
and maximum (D05 or D02) PTV dos-
es—where DX is the minimum dose re-
ceived by X% of the volume—in addition 
to the doses delivered to the GTV. Ideally, 
mean dose and the standard deviation of 
the mean dose should be reported as well 
as the afore mentioned dose levels. A sen-
sible conformity index (CI) is the one pro-
posed by Paddick [52]. If possible, this CI 
should be reported.
Normal tissue risk-adapted frac-
tionation is highly recommended, with 
1–10 delivered fractions depending on the 
size and central/peripheral location of the 
target [53].
Several groups independently demon-
strated a clear dose–response relationship 
for local tumor control [54, 55, 56, 57]: 
a minimum biologically effective dose 
(BED; α/β ratio: 10 Gy) of >100 Gy to the 
PTV) achieved local tumor control rates 
>90%. It could be demonstrated that this 
dose-dependent increase in local control 
translated into improved OS [54, 58]. A 
recent meta-analysis reported the best 
OS rates for medium to high SBRT dos-
es of 83.2–146 Gy BED; OS was worse af-
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ter SBRT with >146 Gy BED, indicating a 
detrimental effect of excessively high dos-
es [59].
Three fractions of 15 Gy with a dose 
maximum of 150% was the preferred frac-
tionation scheme in the German and Aus-
trian patterns of care analysis and resulted 
in local tumor control rates of >90% [60]. 
This fractionation scheme of 3×15 Gy as 
D95 or D98 to the PTV with a D05 or 
D02 PTV dose of 150% is therefore recom-
mended for peripherally located NSCLC 
≤5 cm in diameter. However, it has to be 
mentioned that this regimen was planned 
using type A (pencil beam) dose calcu-
lation algorithms in 80% of cases, which 
might have overestimated the true dose 
by about 10% [61]. Additionally, this rec-
ommendation is lower than the 3×18 Gy 
fractionation scheme that is used most 
frequently internationally.
Limited data are available concern-
ing the safety and efficacy of SBRT for 
centrally located lesions [62]. Particular-
ly where very high single fraction doses 
were applied, lethal outcomes have been 
observed [63]. Therefore, treatment of 
central lesions should preferably be per-
formed within prospective trials such as 
the European Organisation for Research 
and Treatment of Cancer (EORTC) Lung-
TECH trial. Until then, a recommend-
ed fractionation scheme for experienced 
centers is 8×7.5 Gy as D95 or D98 to the 
PTV; dose inhomogeneity within the PTV 
should be limited to 125% [62].
OAR tolerance doses
It is of utmost importance to note that 
none of the published tolerance doses for 
SBRT have been formally validated. Nev-
ertheless, as the toxicity after SBRT for pe-
ripheral lesions with the published OAR 
tolerance doses seems to be acceptable 
(grade ≥ II less than 10%), adherence to 
such published protocols is strongly rec-
ommended (. Tab. 1).
Patients need to be informed about 
the following SBRT-specific toxicities: (1) 
Toxicities in up to 10% of cases depend-
ing on tumor size and location: radia-
tion-induced pneumonitis, rib fractures, 
chest wall pain. (2) Rarely observed tox-
icities: pleural and pericardial effusion, 
stricture of central airway structures, dys-
pnea, bleeding. (3) For more central loca-
tions, the low risk of life-threatening ne-
crosis/fistula of neighboring organs such 
as esophagus, bronchi and large vessels, 
as well that of cardiac arrhythmias should 
be mentioned (depending on the exact tu-
mor location).
Treatment planning
Photon energy should be below 10 MeV 
in order to avoid excess penumbra blur-
ring. A leaf width of 5 mm at the isocen-
ter is considered sufficiently small. The 
voxel size of the calculation grid should 
be 2 mm or less.
For dose calculation, heterogeneity 
correction and use of a type B dose cal-
culation algorithm [64] is mandatory to 
achieve an accuracy of dose calculation 
exceeding 2%.
All prospective trials used three-di-
mensional conformal radiotherapy (3D-
CRT) for treatment planning. Intensity-
modulated radiotherapy (IMRT) and ad-
vanced rotational techniques like volu-
metric-modulated arc therapy (VMAT) or 
RapidArc (Varian Medical Systems, Palo 
Alto, CA, USA) have the potential to in-
crease conformity and homogeneity. The 
biological effect of these differences and 
the potential interplay of multileaf colli-
mator (MLC) and tumor motion need to 
be considered. Flattening filter free irra-
diation will further reduce treatment de-
livery times.
Patient immobilization and setup
Customized patient immobilization was 
used in the majority of trials and is highly 
recommended to minimize intrafraction-
al patient motion.
Internal shifts of the pulmonary target 
relative to the bony structures are the ma-
jor source of positioning uncertainties [65, 
66]. These effects cannot be countered by 
stereotactic setup or bone imaging. There-
fore, daily pretreatment imaging is re-
quired for online correction of setup er-
rors and base-line shifts. Imaging needs to 
visualize either the lung tumor directly or 
implanted markers that act as a surrogate 
for tumor position. Breathing-induced 
target motion must be fully integrated in-
to the image-guided radiotherapy (IGRT) 
process. Post- and/or mid-SBRT imaging 
Tab. 1 Normal tissue constraints according to published major clinical studies. Radiation Therapy Oncology Group (RTOG) protocols can be 











Trachea and large bronchus Dmax 20.2 Gy Dmax 30 Gy Dmax 34.8 Gy
15.6 Gy <4 cc
Dmax 105%a
18 Gy <5 ccb
Dmax 44 Gy
Heart Dmax 22 Gy
16 Gy <15 cc
Dmax 30 Gy Dmax 34 Gy
28 Gy <15 cc
Dmax 105%a
32 Gy <15 cc
–
Esophagus Dmax 15.4 Gy
11.9 Gy <5 cc
Dmax 25.2 Gy
17.7 G <5 cc
Dmax 30 Gy
18.8 Gy <5 cc
Dmax 105%a
27.5 Gy <5 ccb
Dmax 40 Gy
Brachial plexus Dmax 17.5 Gy
14 Gy <3 cc
Dmax 24 Gy
20.4 Gy <3 cc
Dmax 27,2 Gy
23.6 Gy <3 cc
Dmax 32 Gy
30 Gy <3 cc
Dmax 36 Gy
Chest wall Dmax 30 Gy
22 Gy <1 cc
30 Gy <30 cc
60 Gy <3 cc [77, 78]
Dmax 27,2 Gy
32 Gy <1 cc
30 Gy <30 cc
60 Gy <3 cc [77, 78]
–
Spinal cord Dmax 14 Gy
10 Gy <0.35 cc
Dmax 18 Gy 
(RTOG 0236)
Dmax 26 Gy
28.8 Gy <0.35 cc
Dmax 30 Gy
22.5 Gy <0.25 cc
Dmax 28 Gy
aPTV prescription bVolume constraint for non-adjacent wall Dmax maximum dose.
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is recommended for QA, particularly in 
single fraction SBRT. Several methodolo-
gies for image guidance are commercially 
available (cone beam CT, in-room CT and 
orthogonal x-rays for fiducial control) and 
superiority of one method over the other 
has not been demonstrated. 
Interfractional tumor shifts might oc-
cur towards critical OARs and their cor-
rection by IGRT isocenter adjustment 
might result in increased OAR doses. Vol-
umetric IGRT is required to visualize and 
quantify such effects. Methods for avoid-
ing OAR overdosage are incorporation of 
safety margins for critical OARs (planning 
organ at risk volume, PRV, concept), re-
positioning or even replanning if critical 
thresholds are exceeded.
Follow-up
Clinical and radiological follow-up should 
be performed at the treating institution. 
CT imaging should be performed every 
3 months for 2 years and every 6 months 
thereafter for another 3 years. This exam-
ination frequency has not been validat-
ed and should be adjusted to the patient’s 
performance status and suitability for sal-
vage treatment.
Mass-like fibrosis within the high-
dose region is observed after the majori-
ty of SBRT treatments [67, 68, 69, 70] and 
its differentiation from local failure is dif-
ficult. FDG-PET is recommended in cas-
es where CT-based morphological dif-
ferentiation of fibrosis and recurrence is 
not possible. However, FDG-PET results 
should be interpreted with caution with-
in 6–9 months after SBRT due to the pos-
sibility of false-positive findings arising 
from inflammation processes [71]. Due to 
the risk of bleeding, bronchoscopic and/
or transthoracic biopsies are only recom-
mended if local recurrence is suspected 
and clinically relevant salvage treatment 
options are available.
Physical and QA requirements 
for safe SBRT practice
It is recommended that SBRT be per-
formed by a team consisting of a radiation 
oncologist, a medical physicist and tech-
nicians (radiographers, therapists). All 
members of the team should have attend-
ed dedicated SBRT teaching activities or-
ganized within the institution, by nation-
al or international societies or in an indus-
trial setting.
Treatment should follow written stan-
dard operating procedures (SOPs), which 
are adjusted according to national regu-
lations, the institution-specific equipment 
and training and education of the individ-
ual radiotherapy team members.
Comprehensive practical guidelines 
for SBRT are given in several internation-
al reports [5, 6, 7, 8, 47]. For Germany it 
is recommended to apply the appropriate 
norms defined by the Deutsche Institut 
für Normung (DIN). In this context the 
following reports are particularly relevant: 
DIN 6847-5, DIN 6858-1, DIN 6870-1, 
DIN 6873-5, DIN 6875-1 and DIN 6875-2.
Verification of the accuracy of the en-
tire SBRT treatment chain is mandato-
ry. This includes all imaging processes, 
the dose calculation engine, the MLC se-
quencing, the monitor unit calculation, 
the monitor calibration, patient position-
ing, the tracking or gating devices and so 
forth. Most steps are part of the regular 
commissioning and QA procedures.
It is paramount to verify that the ra-
diation isocenter coincides with the me-
chanical isocenter—including couch rota-
tion—and that the lasers are aligned to the 
radiation isocenter. The same is true for 
the imaging isocenter. End-to-end tests 
are recommended for overall uncertain-
ty estimates. If a sufficiently precise inde-
pendent and redundant localization is not 
used for every application, the alignment 
of the IGRT and the treatment isocenter 
should be tested daily.
Radiobiological 
considerations of SBRT
Detailed understanding of the radiobiol-
ogy of SBRT is still lacking. In contrast to 
conventional fractionated radiotherapy, 
there is no repopulation, reoxygenation or 
redistribution of tumor cells in single frac-
tion SBRT. Even hypofractionated sched-
ules still provide short overall treatment 
times and therefore at least accelerated re-
population has not to be considered. Ad-
ditional effects of high fraction doses in 
SBRT may be vascular and [72] immune 
effects [73].
Although the linear quadratic (LQ) 
model is widely used in the community 
and has proven feasible for the descrip-
tion of SBRT outcome in several clinical 
reports, the applicability of this modali-
ty has been questioned because it has not 
been validated for very high single doses 
[74]. Most likely it is accurate up to sin-
gle fraction doses of 15 Gy [75]. For high-
er fraction doses the model might over-
estimate the biological effectiveness, par-
ticularly for low α/β values. This may lead 
to underdosage of tumors with lower α/β 
values, such as prostate cancer, whereas it 
may be less critical for tumors with high-
er α/β values, such lung cancer. Howev-
er, for normal tissues it should provide a 
more conservative approach. Alternative 
models have been proposed but are more 
complicated to use and have not been bet-
ter validated using clinical data. In conclu-
sion, the LQ model should be used, with 
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